ANRO — Alto Neuroscience, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1999480 ·
Last close
$24.91
Market Cap
$999.16M
52W High
$37.48
52W Low
$12.51
ADV30
647,338
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -27,225,000 | -25,124,000 | 326,505,000 | 319,344,000 | 29,975,000 |
| Jun 2026 | 0 | — | -29,129,000 | -27,638,000 | 254,066,000 | 243,733,000 | 34,817,000 |
| Mar 2026 | 0 | — | -27,138,000 | -26,237,000 | 276,259,000 | 263,762,000 | 32,890,000 |
| Dec 2025 | 0 | — | -17,055,000 | -16,182,000 | 184,689,000 | 176,484,000 | 33,547,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-79,123,000
Investing CF
$-556,000
Financing CF
$261,218,000
CapEx
$-580,000
Dividends Paid
—
Buybacks
$-5,774,000
EPS Diluted TTM
$-2.51
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-280,633,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-93,107,000
Pretax Income TTM
$-95,181,000
Interest Exp TTM
$2,074,000
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -66,364,000 | -63,238,000 | 184,689,000 | 33,547,000 | 151,142,000 | -51,769,000 |
| Dec 2024 | 0 | -68,610,000 | -61,431,000 | 177,542,000 | 26,082,000 | 151,460,000 | -47,424,000 |
| Dec 2023 | 0 | -37,809,000 | -36,305,000 | 86,628,000 | 158,300,000 | -71,672,000 | -33,448,000 |
| Dec 2022 | 0 | -27,455,000 | -27,710,000 | 50,854,000 | 89,260,000 | -38,406,000 | -20,394,000 |
TTM Snapshot
Revenues TTM
$6,766,000
NetIncome TTM
$-84,238,000
OpCashFlow TTM
—
Assets (Latest)
$254,066,000
Forward EPS
$-2.99
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $25.91 · call volume: 50 · put volume: 156
Expected Move to 2027-01-15:
±$7.70
(29.72%) —
implied range
$18.21 –
$33.61
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYRX | Cryoport, Inc. | $999.81M | $19.74 | — |
| OMER | OMEROS CORP | $1.01B | $13.92 | — |
| SVRA | Savara Inc | $988.39M | $4.48 | — |
| JBIO | Jade Biosciences, Inc. | $979.40M | $15.40 | — |
| MTRI | InMed Pharmaceuticals Inc. | $1.02B | $17.50 | — |
News headlines (Yahoo Finance, 1h cache)
Alto Neuroscience (ANRO) Reports Wider Quarterly Loss, Is The Premium Valuation Still Justified?
2026-11-19 01:12 · Yahoo
Alto Neuroscience, Inc. (ANRO) Upgraded to Buy: Here's What You Should Know
2026-11-16 16:00 · Yahoo
Wall Street Analysts Predict a 29.38% Upside in Alto Neuroscience, Inc. (ANRO): Here's What You Should Know
2026-11-16 13:55 · Yahoo
Alto Neuroscience faces pivotal 2027 as Jefferies flags three clinical catalysts
2026-11-11 20:44 · Yahoo
Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-10 21:05 · Yahoo
Alto Neuroscience (ANRO) Stock Looks Fully Priced On Book Value
2026-11-10 08:10 · Yahoo
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
2026-11-03 13:03 · Yahoo
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
2026-08-27 20:05 · Yahoo
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued?
2026-08-16 20:07 · Yahoo
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline?
2026-08-16 08:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.